id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2024-E-3875-0006,FDA,FDA-2024-E-3875,Determination of Regulatory Review Period for Purposes of Patent Extension; RYTELO,Notice,Determinations,2026-02-13T05:00:00Z,2026,2,2026-02-13T05:00:00Z,2026-04-15T03:59:59Z,2026-02-20T20:30:13Z,2026-02903,1,0,09000064b91a8f33
FDA-2024-E-3875-0005,FDA,FDA-2024-E-3875,Letter to U. S. Patent and Trademark Office,Other,Letter(s),2025-11-24T05:00:00Z,2025,11,2025-11-24T05:00:00Z,,2025-11-25T02:58:16Z,,0,0,09000064b908e3f3
FDA-2024-E-3875-0004,FDA,FDA-2024-E-3875,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2025-09-11T04:00:00Z,2025,9,2025-09-11T04:00:00Z,,2025-09-11T17:19:18Z,,0,0,09000064b8f528cf
FDA-2024-E-3875-0003,FDA,FDA-2024-E-3875,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2025-08-19T04:00:00Z,2025,8,2025-08-19T04:00:00Z,,2025-08-20T00:36:45Z,,0,0,09000064b8f0823a
FDA-2024-E-3875-0002,FDA,FDA-2024-E-3875,"Patent Extension Application from Bozicevic, Field & Francis LLP (on behalf of Geron Corporation)",Other,Application,2024-08-19T04:00:00Z,2024,8,2024-08-19T04:00:00Z,,2024-08-19T12:46:08Z,,0,0,0900006486644605
FDA-2024-E-3875-0001,FDA,FDA-2024-E-3875,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2024-08-19T04:00:00Z,2024,8,2024-08-19T04:00:00Z,,2024-08-19T12:45:57Z,,0,0,0900006486644603